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I-1 Non-invasive (serum) markers in the diagnosis of
liver ﬁbrosis
H. Van Vlierberghe*. Department of Gastroenterology and
Hepatology, Ghent University Hospital, Belgium
The stellate cell is the key regulator cell in the development
of liver ﬁbrosis and cirrhosis. After an injury (which can be
viral, toxic, auto-immune or metabolic), the stellate cell
gets activated and produces an increase in the extracellular
matrix in the liver; this can lead to ﬁbrosis and cirrhosis.
Patients with severe liver ﬁbrosis and/or end stage liver cir-
rhosis can suffer from jaundice, bleeding from oesophageal
varices, development of ascites and hepatic encephalopathy
and carry a risk to develop a hepatocellular carcinoma. Liver
transplantation is at this moment the only ‘curative’ option.
If a liver transplantation is not possible, these ﬁbrosis re-
lated complications often lead to the death of the patient.
Although the diagnosis of liver ﬁbrosis is made by an invasive
liver biopsy, this ‘golden standard’ carries a substantial
number of complications and inter- and/or intra agreement
correlations are not optimal. Recently the interest for non-
invasive (serum) markers for liver ﬁbrosis have been studied.
The features of an ideal marker for liver ﬁbrosis are:
• Liver speciﬁc
• Levels not inﬂuenced by alterations in liver, renal or
reticuloendothelial function
• Measurement of one of more of the following processes
Stage of ﬁbrosis
Activity of matrix deposition
Activity of matrix removal
• Easy to perform
Actually there are direct and indirect markers of liver
ﬁbrosis. A direct marker is a marker of matrix turnover
with relationship to ECM deposition and removal. Indirect
markers use ‘standard’ laboratory test which have not
necessary direct correlation to matrix turnover. However
these actual markers (direct and indirect), although
promising, lack perfomance in earlier stages of ﬁbrosis.
They also need validation by independent groups.
Liver stifness measurement by elastography is an alternative
promising non-invasive technique to distinguish mild from
severe ﬁbrosis.
I-2 Insight into new markers and diagnostic models on
hepatocellelar carcinoma
C.F. Gao, M.C. Wu. Eastern Hepatobiliary Hospital, Second
Military Medical University, Shanghai 200438, China
The incidence of hepatocellular carcinoma (HCC) is
increasing worldwide. The overall survival of patients
with HCC is grim because most patients are diagnosed
late, when curative treatment is not possible. So early
diagnosis of hepatocelluar carcinoma (HCC) is still a great
challenge for clinical practice. Image techniques as well
as pathological examination are expensive or invasive and
operator dependent. Obviously, serum markers of HCC are
desperately required so as to make early diagnosis and
patient’s follow up practical. The ideal biomarkers should be
sensitive, speciﬁc, noninvasive, reproducible, inexpensive
and acceptable to patients. Up to now, the so called tumor
markers like AFP, liver enzymes, cytokines as well as some
special glycoproteins, though helpful, are not sensitive and
speciﬁc enough for HCC early diagnosis.
On the other hand, the knowledge on independent predic-
tors of HCC is increasing. These predicators include virus
infection, BMI (body mass index), diabetes, low platelet
count or some special genotypes of predisposing genes.
The establishment of several interesting predictive
diagnostic models on liver ﬁbrosis/cirrhosis suggests that
mathematic predictive model, based on large sample
size and follow up study, might be of higher sensitivity,
speciﬁcity and feasibility in clinical application. According
to our preliminary research, here we suggest to pay
attention to the establishment and application of this kind
of multiparameter diagnostic models clinically, so as to
improve the early diagnosis of HCC in a more economical
and feasible way.
In summary, although many studies of newer tumor markers
as well as independent predicators have been published, the
existing comments on these markers have many limitations.
These newer markers, including GPC-3, GP73, AFP-L3, as
well as our suggested putative multiparameters diagnostic
models should be evaluated further in properly designed
collaborative longitudinal studies.
I-3 The Ras inhibitor farnesylthiosalicyclic acid (FTS)
prevents nodule formation and development of
preneoplastic foci of altered hepatocytes in rats
T. Schneider-Merck1, I. Borbath1,2, N. Charette1, C. De
Saeger1, J. Abarca1, I. Leclercq1, Y. Horsmans1,2 *,
P. Sta¨rkel1,2. 1Laboratory and 2Department of
Gastroenterology, St. University Hospital, Universite´
catholique de Louvain, 1200 Brussels, Belgium
Background and Aims: Aberrant activation of oncogenes,
such as Ras, likely contributes to the development
of hepatocarcinoma (HCC) making Ras a target for
cancer therapy. We evaluated in vivo the effect of
intraperitoneal injection of the Ras inhibitor S-trans, trans-
farnesylthiosalicyclic acid (FTS) on Ras activation and the
development of preneoplastic liver lesions in rats repeatedly
injected with diethylnitrosamine (DEN).
Methods and Results: FTS prevents the development of
macroscopic liver nodules and reduces liver expression and
overall surface of the tumour marker GSTp as assessed by
Western blotting and immunohistochemistry. FTS abrogates
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DEN-induced Ras membrane activity and induces apoptosis
in transformed hepatocytes as indicated by high liver
caspase 3 activity and an increased number of Tunel positive
cells in GSTp-expressing hepatocytes. Apoptosis induction is
associated with up-regulation of Fas, Fas ligand and JNK
phosphosphorylation that occurs independently of TNFa and
Trail. Bax, Bcl2, Bcl-xl expression and cytochrome C release
is not affected by FTS.
Conclusions: FTS inhibits Ras activation in the liver
and prevents preneoplastic liver nodule development by
inducing apoptosis in transformed hepatocytes. FTS-induced
apoptosis is related to activation of the extrinsic pathway
involving the Fas/Fas ligand system. Therefore, FTS might
be a promising agent for the development of new
therapeutic strategies in HCC.
I-4 Blood sugar test: non-invasive diagnosis for liver
diseases
C. Chen*. Department of Molecular Biology, Ghent
University and Department for Molecular Biomedical
Research, VIB, Gent, Belgium
Hepatocellular carcinoma (HCC), also known as primary
liver cancer, is the ﬁfth most common cancer worldwide. No
completely accurate screening test for liver cancer exists.
Doctors sometimes use a blood test that checks for the
presence of alpha-fetoprotein (AFP) a type of protein not
normally found in adults to screen people at high risk of
the disease.
Unfortunately, an elevated level of AFP is detectable in
only about two-thirds of patients with early-stage HCC,
and high mortality from HCC is due to the inability to
detect these cancers in their earliest stages. Thus, to detect
small tumors, a very sensitive biomarker is needed, with
an intensity that should be proportional to the size of the
tumor.
Protein glycosylation, the most common form of co-
translational modiﬁcation of proteins, is the enzymatic
addition of sugars or oligosaccharides (or glycans) to
proteins. Protein glycosylation increases the diversity of
the functions of proteins encoded in the genome. The result
is that different glycomes of the same protein may have
different functional, kinetic or physical properties. Because
the condition of the cells largely regulates glycosylation
pathway, the type of glycan produced by cells, tissue, or
organism could reﬂect their current physiological state.
This means that the sugar chains can be altered by the
physiological or pathophysiological condition of the cell.
Our group took advantage of a recently developed technique
to study the total glycome (N-linked sugars) pattern of
protein mixtures, e.g. serum proteins. Sugar trees are cut
from the proteins, collected and separated. We have been
able to analyze the serum samples of over 500 cirrhosis
patients. It was clear that the changes in serum glycome
correlated with the presence of tumors and with tumor
size. This study included 450 HBV-infected patients with
liver ﬁbrosis, cirrhosis and HCC. We found that a branch
alpha(1,3)-fucosylated triantennary glycan (NA3Fb) was
more abundant in HCC patients than in cirrhosis patients,
ﬁbrosis patients and healthy blood donors, whereas a
bisecting core alpha (1,6)-fucosylated biantennary glycan
(NA2FB) was elevated in cirrhosis patients. The ratio of
these values forms the basis of the new blood test (the
log ratio of peak9/peak7, renamed as GlycoHCCTest). Using
GlycoHCCTest, we were able to make the correct diagnosis
in 70% of the cases, a success rate that equals that of the
AFP tumor marker currently used in the clinic. Promisingly,
when the AFP test was used in combination with the new
GlycoHCCTest, the accuracy of HCC diagnosis increased
dramatically. The new glycomic test succeeded in detecting
the liver cancer in more than half of the patients with
cirrhosis and cancer of the liver for whom the AFP test was
inconclusive.
I-5 HBV genome oncogenic mutations in Chinese HCC
patients related to chronic HBV infection
F.M. Lu*, S.Z. Jiang, X.M. Chen, H. Zhuang. Department
of Microbiology, Peking University Health Science Center,
Beijing, 100191, China
Aims: To identify the HBV oncogenic mutations associated
to the Chinese patients with HCC.
Method: For mutation screening, HBV preS/S gene, X gene
and precore region were ampliﬁed from liver tumor and
their matched paratumor tissue by PCR and analyzed by
direct sequencing. Cassette ligation mediated PCR was used
to analyze HBx integration mutation.
Results: HBV mutation was analyzed in 41 tumor tissues
and 33 non-tumor tissues (among them 32 were paired).
Phylogenetic analysis revealed that 87.3% strains were
genotype C, 8% genotype B, 1.6% genotype D, 3.1%
genotype A. From these samples, pre-S/S gene and X gene
and precore regions from 110 sequences were analyzed
separately. X gene’s carboxyl-terminal deletion (from 6 to
114 amino acids) was found in 20/38 (52.6%) of tumor
samples and only in 9/30 (30%) of paratumor samples.
Concordant to our previous work, pre-S1 start codon in-
frame deletion, pre-S2 start codon mutation and pre-S2
in-frame deletion were all detected in both tumor tissue
and paratumor tissues tested, with a higher tendency
in tumor samples. Interestingly, pre-S1 deletion involving
the S promoter was found in 5 tumor tissue while none
in the paired paratumor tissues, indicating the tumor
associated mutation. However, it is noteworthy that a
higher T1762/A1764 mutation and precore A1896 mutation
frequencies were found in our study: T1762/A1764 mutation
or deletion in 31/41 (75.6%) of tumor samples and in
26/30 (86.7%) paratumor samples; the A1896 mutation
or deletion in 24/37 (64.9%) tumor samples and in
19/28(67.9%) paratumor sample, though there was no
signiﬁcant difference. HBx integration was detected in 7/32
HCC samples and only in 1/22 paratumor samples (among
them 19 were paired). In 2 tumor samples, 2 different
HBx integration sites were found. Ten of 11 integration
events resulted in HBx C-terminal truncated mutations,
except 1 interstitial deletion within the HBx gene in a
tumor sample. Interestingly, though the integration sites in
human genome was random, 5 of 11 breaking sites (4 in the
tumor and 1 in the paratumor sample) were within the DR1
sequence.
Conclusion: Pre-S1 deletion involved S promoter sequence
was only demonstrated in tumor tissues and indicated such
mutation was probably oncogenic; HBx carboxyl-terminal
deletion were more common in tumor than in paratumor
tissues tested, implicating a role in liver carcinogenesis.
In contrast to several previous reports, high frequency
mutations involving pre-S2 gene, X gene, BCP, T1762/A1764
and pre-C A1896 were found in both tumor and paratumor
tissues with no signiﬁcant difference. It is suggested that
such mutations were simply as a result of accumulation with
time of persistent infection and not oncogenic.
I-6 Risks and results of the living related liver
transplantation in Europe
B. de Hemptinne*. Department of Surgery, University
Hospital of Ghent, Belgium
The European Liver Transplantation registree (ELTR) has
cumulated data concerning 54,133 cadaveric full-size
